Intradermal Influenza Vaccination
Recruiting now · Early Phase 1
Conditions studied: Vaccine Reaction
In brief
The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after vaccination. The primary objective is to identify baseline correlates of immune response in the skin and peripheral blood to the seasonal influenza vaccine. The investigators secondary goals are to describe the inflammatory response in the skin over time.
Key facts
- Study ID
- NCT06067555
- Run by
- Yale University
- People needed
- 249
- Starts
- 2024-01-24
- Expected to finish
- 2026-05-01
- Last updated by the study team
- 2025-06-19
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.
Where it is running
- Church Street Research Unit — New Haven, Connecticut, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.